Spironolactone Use And Neurocognitive Outcomes Among Patients With Heart Failure And Reduced Ejection Fraction

Paola Pastena,Hal Skopicki,Marc Halterman,Andreas Kalogeropoulos

DOI: https://doi.org/10.1016/j.cardfail.2023.10.337

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background Spironolactone may play a role in preventing cognitive impairment and Alzheimer's disease (AD). High plasma aldosterone is associated with increased risk of cognitive impairment in patients with hypertension, and the administration of spironolactone has been shown to attenuate cognitive decline in mouse models of type 2 diabetes mellitus and Alzheimer's disease. These findings suggest that spironolactone may hold promise as a neuroprotective intervention for patients with heart failure (HF), which is known to be associated with cognitive impairment and accelerated cognitive decline. Hypothesis We hypothesized that the use of spironolactone in patients with HF and reduced ejection fraction (HFrEF) is associated with lower 3-year incidence of new neurocognitive diagnoses (AD, dementia and cognitive decline) compared to patients with HFrEF not receiving the medication. Methods Using data from the TriNetX electronic health records network (US Network), we examined relevant outcomes in (1) a spironolactone cohort, comprising of adults with HFrEF (ICD-10 I50.2) who received spironolactone between 2015 and 2019 (to allow for ≥3 years of follow up) and (2) a propensity score-matched (for >100 clinical characteristics) HFrEF cohort not receiving spironolactone during the same period. We evaluated for new: (1) AD (ICD-10: G30); (2) dementia (ICD-10: F01-F03); and (3) any cognitive decline (ICD-10: R41.8). We used Cox proportional hazards models after excluding patients with outcomes prior to the time window to compare incidence. Results The baseline characteristics of the matched cohorts (N = 44,892 for each) were well balanced (Table 1); all standardized mean differences were <0.1, indicating adequate matching. After 3 years of follow up, the risk of developing AD (hazard ratio [HR] 0.82; 95% CI: 0.72, 0.94; P=0.005) and dementia (HR 0.91; 95% CI: 0.85, 0.97; P=0.006) was lower among spironolactone recipients, Table 2. However, no difference in the incidence of cognitive decline was observed (HR 0.97; 95% CI: 0.93, 1.02; P=0.226). Conclusions The incidence of neurocognitive diagnoses was lower among spironolactone recipients in this propensity-matched analysis of patients with HFrEF from a large healthcare database. These findings suggest that spironolactone may have neuroprotective effects in HFrEF, but further research is needed to confirm these results.

cardiac & cardiovascular systems